Ascentage Pharma Group International
HKEX:6855
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.65
90.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Ascentage Pharma Group International
Interest Income Expense
Ascentage Pharma Group International
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Ascentage Pharma Group International
HKEX:6855
|
Interest Income Expense
ÂĄ9.4m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Interest Income Expense
ÂĄ44.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Interest Income Expense
-ÂĄ155.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Interest Income Expense
ÂĄ174.2m
|
CAGR 3-Years
115%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Interest Income Expense
ÂĄ204.9m
|
CAGR 3-Years
214%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Interest Income Expense
ÂĄ69.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ascentage Pharma Group International
Glance View
Ascentage Pharma Group International, a biopharmaceutical company stepping confidently onto the global stage, is driven by a mission to address unmet medical needs in the challenging realm of apoptosis-targeted therapies. Founded in 2009, with roots in both China and the United States, the company has honed its expertise in developing innovative small-molecule therapeutics. Its focus is on diseases inadequately treated by current standards, particularly cancers, hepatitis B, and age-related diseases. By concentrating on inhibiting protein-protein interactions that govern apoptosis, Ascentage Pharma employs sophisticated science to guide its research and development programs. This strategic focus on apoptosis, the programmed cell death process, enables the company to work on promising drug candidates that specifically target the pathways responsible for the survival and proliferation of malignant cells. Revenue generation for Ascentage Pharma is multi-faceted. Primarily, the company earns through partnerships, milestone payments, collaborative agreements, and licensing deals with larger pharmaceutical firms eager to leverage its unique expertise in apoptosis. In addition, its robust pipeline—comprising compounds at various stages of clinical development—provides strategic opportunities for monetization through out-licensing agreements once promising clinical data is established. By creating a symbiotic relationship with its partners, while also advancing its proprietary drug candidates towards commercialization, Ascentage Pharma not only progresses its significant research but also solidifies its financial foundation. The company’s growth is anchored in its ability to translate groundbreaking science into viable treatments that can crucially impact patients’ lives, paving a path to sustained financial and innovative success.
See Also
What is Ascentage Pharma Group International's Interest Income Expense?
Interest Income Expense
9.4m
CNY
Based on the financial report for Jun 30, 2025, Ascentage Pharma Group International's Interest Income Expense amounts to 9.4m CNY.
What is Ascentage Pharma Group International's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-9%
The average annual Interest Income Expense growth rates for Ascentage Pharma Group International have been -53% over the past three years , -9% over the past five years .